Summary
Pyridoxal phosphate is the cofactor for over 100 enzyme-catalysed reactions in the body, including many involved in the synthesis or catabolism of neurotransmitters. Inadequate levels of pyridoxal phosphate in the brain cause neurological dysfunction, particularly epilepsy. There are several different mechanisms that lead to an increased requirement for pyridoxine and/or pyridoxal phosphate. These include: (i) inborn errors affecting the pathways of B6 vitamer metabolism; (ii) inborn errors that lead to accumulation of small molecules that react with pyridoxal phosphate and inactivate it; (iii) drugs that react with pyridoxal phosphate; (iv) coeliac disease, which is thought to lead to malabsorption of B6 vitamers; (v) renal dialysis, which leads to increased losses of B6 vitamers from the circulation; (vi) drugs that affect the metabolism of B6 vitamers; and (vii) inborn errors affecting specific pyridoxal phosphate-dependent enzymes. The last show a very variable degree of pyridoxine responsiveness, from 90% in X-linked sideroblastic anaemia (δ-aminolevulinate synthase deficiency) through 50% in homocystinuria (cystathionine β-synthase deficiency) to 5% in ornithinaemia with gyrate atrophy (ornithine δ-aminotransferase deficiency). The possible role of pyridoxal phosphate as a chaperone during folding of nascent enzymes is discussed. High-dose pyridoxine or pyridoxal phosphate may have deleterious side-effects (particularly peripheral neuropathy with pyridoxine) and this must be considered in treatment regimes. None the less, in some patients, particularly infants with intractable epilepsy, treatment with pyridoxine or pyridoxal phosphate can be life-saving, and in other infants with inborn errors of metabolism B6 treatment can be extremely beneficial.
Similar content being viewed by others
References
An SJ, Park SK, Hwang IK, et al (2004) Vigabatrin inhibits pyridoxine-5′-phosphate oxidase, not pyridoxal kinase in the hippocampus of seizure prone gerbils. Neurochem Int 44: 133–137.
Aoki Y, Muranaka S, Nakabayashi K, Ueda Y (1979) delta-Aminolevulinic acid synthetase in erythroblasts of patients with pyridoxine-responsive anemia. Hypercatabolism caused by the increased susceptibility to the controlling protease. J Clin Invest 64: 1196–1203.
Apeland T, Mansoor MA, Pentieva K, McNulty H, Seljeflot I, Strandjord RE (2002) The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res 51: 237–247.
Barber GW, Spaeth GL (1969) The successful treatment of homocystinuria with pyridoxine. J Pediatr 75: 463–478.
Baxter P (2001) Pyridoxine dependent/responsive seizures. In: Baxter P, ed. Vitamin Responsive Conditions in Paediatric Neurology. London: MacKeith Press, 109–165.
Been JV, Bok LA, Andriessen P, Renier WO (2005) Epidemiology of pyridoxine-dependent seizures in The Netherlands. Arch Dis Child 90: 1293–1296.
Bender DA (1999) Non-nutritional uses of vitamin B6. Br J Nutr 81: 7–20.
Berson EL, Schmidt SY, Shih VE (1978) Ocular and biochemical abnormalities in gyrate atrophy of the choroid and retina. Ophthalmology 85: 1018–1027.
Berson EL, Shih VE, Sullivan PL (1981) Ocular findings in patients with gyrate atrophy on pyridoxine and low-protein, low-arginine diets. Ophthalmology 88: 311–315.
Biehl JP, Vilter RW (1954) Effects of isoniazid on pyridoxine metabolism. J Am Med Assoc 156: 1549–1552.
Bilski P, LiMY, Ehrenshaft M, Daub ME, Chignell CF (2000) Vitamin B6 (pyridoxine) and its derivatives are efficient singlet oxygen quenchers and potential fungal antioxidants. Photochem Photobiol 71: 129–134.
Cormier-Daire V, Dagoneau N, Nabbout R, et al (2000) A gene for pyridoxine-dependent epilepsy maps to chromosome 5q31. Am J Hum Genet 67: 991–993.
Cotter PD, May A, Fitzsimons EJ, et al (1995) Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 96: 2090–2096.
Coursin DB (1954) Convulsive seizures in infants with pyridoxine-deficient diet. J Am Med Assoc 154: 406–408.
Dalton K, Dalton MJ (1987) Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 76: 8–11.
Ebinger M, Schultze C, Konig S (1999) Demographics and diagnosis of pyridoxine-dependent seizures. J Pediatr 134: 795–796.
Ehrenshaft M, Bilski P, Li MY, Chignell CF, Daub ME (1999) A highly conserved sequence is a novel gene involved in de novo vitamin B6 synthesis. Proc Natl Acad Sci USA 96: 9374–9378.
Eliot AC, Kirsch JF (2004) Pyridoxal phosphate enzymes: mechanistic, structural and evolutionary considerations. Annu Rev Biochem 73: 383–415.
Erlandsen H, Pey AP, Gámez A, et al (2004) Correction of kinetic and stability defects by terahydrobiopterin in phenylketonuria with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 101: 16903–16908.
Farrant RD, Walker V, Mills GA, Mellor JM, Langley GJ (2001) Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II. J Biol Chem 276: 15107–15116.
Fouts PJ, Lepkovsky S (1942) A green pigment-producing compound in urine of pyridoxine-deficient dogs. Proc Soc Exp Biol Med 50: 221–222.
Furuyama K, Fujita H, Nagai T, et al (1997) Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation in the erythroid 5-aminolevulinate synthase gene. Blood 90: 822–830.
Glenn GM, Krober MS, Kelly P, McCarty J, Weir M (1995) Pyridoxine as therapy in theophylline-induced seizures. Vet Hum Toxicol 37: 342–345.
Greengard O, Gordon M (1963) The cofactor-mediated regulation of apoenzyme levels in animal tissues. I. The pyridoxine-induced rise of rat liver tyrosine transaminase level in vivo. J Biol Chem 238: 3708–3710.
Gross-Mesilaty S, Hargrove JL, Ciechanover A (1997) Degradation of tyrosine aminotransferase (TAT) via the ubiquitin-proteasome pathway. FEBS Lett 405: 175–180.
Hallert C, Grant C, Grehn S, et al (2002) Evidence of poor vitamin status in coeliac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther 16: 1333–1339.
Hammen A, Wagner B, Berkhoff M, Donati F (1998) A paradoxical rise of neonatal seizures after treatment with vitamin B6. Eur J Paediatr Neurol 2: 319–322.
Hunt AD Jr, Stokes J Jr, McCrory WW, Stroud HH (1954) Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine. Pediatrics 13: 140–145.
Iqbal SJ, Brain A, Reynolds TM, Penny M, Holland S (1998) Relationship between serum alkaline phosphatase and pyridoxal-5′-phosphate levels in hypophosphatasia. Clin Sci (Lond) 94: 203–206.
Kennaway NG, Weleber RG, Buist NRM (1980) Gyrate atrophy of the choroid and retina with hyperornithinaemia: biochemical and histological studies and response to vitamin B6. Am J Hum Genet 32: 529–541.
Kowlessar OD, Haefner LJ, Benson GD (1964) Abnormal tryptophan metabolism in patients with adult celiac disease, with evidence for deficiency of vitamin B6. J Clin Invest 43: 894–903.
Kretsch MJ, Sauberlich HE, Newbrun E (1991) Electroencephalographic changes and periodontal status during short-term vitamin B-6 depletion of young, nonpregnant women. Am J Clin Nutr 53: 1266–1274.
Lee P, Kuhl W, Gelbart T, et al (1994) Homology between a human protein and a protein of the green garden pea. Genomics 21: 371–378.
Levine S, Saltzman A (2004) Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol 24: 497–500.
Litmanovitz I, Reish O, Dolfin T, et al (2002) Glu274Lys/Gly309Arg mutation of the tissue-nonspecific alkaline phosphatase gene in neonatal hypophosphatasia associated with convulsions. J Inherit Metab Dis 25: 35–40.
Mackey AD, Lieu SO, Carman C, Gregory JF (2003) Hydrolytic activity towards pyridoxine-5-β-d-glucoside in rat intestinal mucosa is not increased by vitamin B-6 deficiency: effect of basal diet composition and pyridoxine intake. J Nutr 133: 1362–1367.
McCormick DB, Snell EE (1961) Pyridoxal phosphokinases. II. Effects of inhibitors. J Biol Chem 236: 2085–2088.
McKinley MC, McNulty H, McPartlin J, et al (2001) Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. Am J Clin Nutr 73: 759–764.
Mills PB, Surtees RAH, Champion MP, et al (2005) Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5′-phosphate oxidase. Hum Mol Genet 14: 1077–1086.
Mills PB, Struys E, Jakobs C, et al (2006) Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nature Medicine 12: 307–309.
Morrison LA, Driskell JA (1985) Quantities of B6 vitamers in human milk by high-performance liquid chromatography. Influence of maternal vitamin B6 status. J Chromatogr 337: 249–258.
Mudd SH, Levy HL, Kraus JP (2001) Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2007–2056.
Namazi MR (2003) Pyridoxal 5′-phosphate as a novel weapon against autoimmunity and transplant rejection. FASEB J 17: 2184–2186.
ParkYK, Linkswiler H (1971) Effect of vitamin B6 depletion in man on the plasma concentration and the urinary excretion of free amino acids. J Nutr 101: 185–191.
Perez-Llarena, FJ, Rodriguez-Garcia A, Enguita FJ, et al (1998) The pcd gene encoding piperideine 6-carboxylate dehydrogenase involved in biosynthesis of alpha-aminoadipic acid is located in the cephamycin cluster of Streptomyces clavuligerus. J Bacteriol 180: 4753–4756.
Plecko B, Stockler-Ipsiroglu S, Paschke E, Erwa W, Struys EA, Jakobs C (2000) Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxine-dependent epilepsy. Ann Neurol 48: 121–125.
Rathbun JC (1948) Hypophosphatasia: a new developmental anomaly. Am J Dis Child 75: 822–831.
Salazar P, Tapia R (2001) Seizures induced by intracerebral injection of pyridoxal-5′-phosphate: effect of GABAergic drugs and glutamate receptor antagonists. Neuropharmacology 41: 546–553.
Salhany JM, Schopfer LM (1993) Pyridoxal 5′-phosphate binds specifically to soluble CD4 protein, the HIV-1 receptor. J Biol Chem 268: 7643–7645.
Sauberlich HE (1999) Vitamin B-6 (pyridoxine). In: Sauberlich HE, ed. Laboratory Tests for the Assessment of Nutritional Status, 2nd ed. Boca Raton: CRC Press, 71–102.
Skvorak AB, Robertson NG, Yin Y, et al (1997) An ancient conserved gene expressed in the human inner ear: identification, expression analysis, and chromosomal mapping of human and mouse antiquitin (ATQ1). Genomics 46: 191–199.
Takagi M, Fukui T, Shimomura S (1982) Catalytic mechanism of glycogen phosphorylase: pyridoxal(5′)diphospho(1)-α-d-glucose as a transition-state analogue. Proc Natl Acad Sci USA 79: 3716–3719.
Tully DB, Allgood VE, Cidlowski JA (1994) Modulation of steroid receptor-mediated gene expression by vitamin B6. FASEB J 8: 343–349.
Ubbink JB, Bissbort S, Vermaak WJ, Delport R (1990a) Inhibition of pyridoxal kinase by methylxanthines. Enzyme 43: 72–79.
Ubbink JB, Delport R, Bissbort S, Vermaak WJ, Becker PJ (1990b) Relationship between vitamin B-6 status and elevated pyridoxal kinase levels induced by theophylline therapy in humans. J Nutr 120: 1352–1359.
Veresova S, Kabova R, Velisek L (1998) Proconvulsant effects induced by pyridoxine in young rats. Epilepsy Res 29: 259–264.
Walker V, Mills GA, Peters SA, Merton WL (2000) Fits, pyridoxine, and hyperprolinaemia type II. Arch Dis Child 82: 236–237.
Wang HS, Kuo MF, Chou ML, et al (2005) Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Arch Dis Child 90(5): 512–515.
Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR (1995) Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nature Genetics 11: 45–51.
Weleber RG, Kennaway NG, Buist NR (1978) Vitamin B6 in management of gyrate atrophy of the choroids and retina. Lancet 2: 1213.
Weleber RG, Kennaway NG (1981) Clinical trial of vitamin B6 for gyrate atrophy of the choroid and retina. Ophthalmology 88: 316–324.
Whyte MP, Mahuren JD, Fedde KN, Cole FS, McCabe ER, Coburn SP (1988) Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5′-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest 81: 1234–1239.
Yoshida I, Sakaguchi Y, Nakano M, Yamashita F, Hitoshi T (1985) Pyridoxal phosphate-induced liver injury in a patient with homocystinuria. J Inherit Metab Dis 8: 91.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Jean-Marie Saudubray
Competing interests: None declared
Rights and permissions
About this article
Cite this article
Clayton, P.T. B6-responsive disorders: A model of vitamin dependency. J Inherit Metab Dis 29, 317–326 (2006). https://doi.org/10.1007/s10545-005-0243-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10545-005-0243-2